Zum Inhalt
Erschienen in:

01.08.2013 | main topic

Advanced basal cell carcinoma

verfasst von: Uwe Wollina, MD, Georgi Tchernev, MD, PhD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 15-16/2013

Einloggen, um Zugang zu erhalten

Summary

Basal cell carcinoma (BCC) is the most common skin malignancy worldwide. Ultraviolet light exposure is the best known exogenous factor in BCC development. This is also the target for primary prevention. Advanced BCC include locally advanced tumors and metastatic tumors. Prognosis is worse compared to stage I and II BCCs. Mohs or micrographically controlled surgery is the gold standard of treatment. In patients with tumors that cannot be completely removed radiotherapy was the only alternative in the past. More recently new drugs for targeted therapy of signaling pathways like sonic hedgehog or epidermal growth factor receptor became available. More small molecules are under investigation. Since the complete response rates are limited, future research has to evaluate their combination with surgery.
Literatur
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Metadaten
Titel
Advanced basal cell carcinoma
verfasst von
Uwe Wollina, MD
Georgi Tchernev, MD, PhD
Publikationsdatum
01.08.2013
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 15-16/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-013-0193-5